Götz M
Padiatr Padol. 1975;10(4):466-73.
Drug combinations play an important role in the day-to-day management of asthmatic out-patients. The long-term use of such a combination (Marax) was assessed in 46 asthmatic children aged 1;6 to 13;8 years who were followed up for a maximum of 7 years. Using a daily dosage of up to 16 mg/kg bodyweight more than 80% of children showed definite improvement leading to prevention or significant reduction of acute attacks and clearly reduced dyspnoeic states between attacks. Patients with very severe forms appeared to be influenced less favourably. Spirometric values were obtained in some of the patients and indicated reduction of obstruction. Patients with intrinsic and extrinsic asthma responded satisfactorily. The value of a long-term prophylactic treatment is discussed. These preliminary results appear to support this form of therapy.
药物组合在哮喘门诊患者的日常治疗中起着重要作用。对46名年龄在1岁6个月至13岁8个月的哮喘儿童进行了评估,这些儿童长期使用这种组合药物(Marax),随访时间最长为7年。使用高达16毫克/千克体重的日剂量时,超过80%的儿童病情有明显改善,从而预防或显著减少了急性发作,并明显减轻了发作间期的呼吸困难状态。病情非常严重的患者似乎受益较少。部分患者进行了肺功能测定,结果显示气道阻塞有所减轻。内源性和外源性哮喘患者的反应令人满意。文中讨论了长期预防性治疗的价值。这些初步结果似乎支持这种治疗方式。